HBsAg-vectored vaccines simultaneously deliver CTL responses to protective epitopes from multiple viral pathogens.
暂无分享,去创建一个
A. Gould | S. Thomson | J. Kattenbelt | R. Tindle | O. Haigh | M. Cochrane | Dekun Chen | Kristy L Edgtton | Huayang Guo | M. Mather
[1] C. Ottensmeier,et al. DNA vaccines: precision tools for activating effective immunity against cancer , 2008, Nature Reviews Cancer.
[2] Bjoern Peters,et al. HLA class I supertypes: a revised and updated classification , 2008, BMC Immunology.
[3] R. Tindle,et al. Multiple copies of a tumor epitope in a recombinant hepatitis B surface antigen (HBsAg) vaccine enhance CTL responses, but not tumor protection. , 2007, Virology.
[4] A. Rickinson,et al. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. , 2007, Annual review of immunology.
[5] S. Wain-Hobson,et al. Optimisation of secretion of recombinant HBsAg virus-like particles: Impact on the development of HIV-1/HBV bivalent vaccines. , 2007, Vaccine.
[6] H. Netter,et al. Hepatitis B Surface Antigen Vector Delivers Protective Cytotoxic T-Lymphocyte Responses to Disease-Relevant Foreign Epitopes , 2006, Journal of Virology.
[7] I. Mackay,et al. Cytotoxic T-Lymphocyte Epitope Vaccination Protects against Human Metapneumovirus Infection and Disease in Mice , 2006, Journal of Virology.
[8] Robert Y. L. Wang,et al. Reduced Secretion of Virions and Hepatitis B Virus (HBV) Surface Antigen of a Naturally Occurring HBV Variant Correlates with the Accumulation of the Small S Envelope Protein in the Endoplasmic Reticulum and Golgi Apparatus , 2005, Journal of Virology.
[9] D. Fuller,et al. Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. , 2005, Vaccine.
[10] I. Berkower,et al. Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120. , 2004, Virology.
[11] R. Seder,et al. DNA vaccination: the answer to stable, protective T-cell memory? , 2003, Current opinion in immunology.
[12] Harald zur Hausen,et al. A Synthetic E7 Gene of Human Papillomavirus Type 16 That Yields Enhanced Expression of the Protein in Mammalian Cells and Is Useful for DNA Immunization Studies , 2003, Journal of Virology.
[13] M. Raje,et al. Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen. , 2002, Journal of biotechnology.
[14] A. Hill,et al. Role of transfection in the priming of cytotoxic T-cells by DNA-mediated immunization. , 2002, Vaccine.
[15] G. Gao,et al. Virus-specific CTL responses induced by an H-2K(d)-restricted, motif-negative 15-mer peptide from the fusion protein of respiratory syncytial virus. , 2002, The Journal of general virology.
[16] A. Suhrbier,et al. Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. , 2001, Vaccine.
[17] C Crimi,et al. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. , 2001, Vaccine.
[18] Steven A. Rosenberg,et al. Progress in human tumour immunology and immunotherapy , 2001, Nature.
[19] T. Macnaughton,et al. Antigenicity and Immunogenicity of Novel Chimeric Hepatitis B Surface Antigen Particles with Exposed Hepatitis C Virus Epitopes , 2001, Journal of Virology.
[20] Mary S. Wu,et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. , 2000, Vaccine.
[21] F. Lemonnier,et al. Multiepitopic HLA-A*0201-Restricted Immune Response Against Hepatitis B Surface Antigen After DNA-Based Immunization , 2000, The Journal of Immunology.
[22] P. Dellabona,et al. Relevance of the Tumor Antigen in the Validation of Three Vaccination Strategies for Melanoma1 , 2000, The Journal of Immunology.
[23] R. Offringa,et al. Differential binding of viral peptides to HLA‐A2 alleles. Implications for human papillomavirus type 16 E7 peptide‐based vaccination against cervical carcinoma , 1999, European journal of immunology.
[24] G Y Ishioka,et al. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. , 1999, Journal of immunology.
[25] A. Fomsgaard,et al. Improved immunogenicity of HIV-1 epitopes in HBsAg chimeric DNA vaccine plasmids by structural mutations of HBsAg. , 1999, DNA and cell biology.
[26] P. Lambert,et al. Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes. , 1998, Virology.
[27] D. Chargelegue,et al. A Peptide Mimic of a Protective Epitope of Respiratory Syncytial Virus Selected from a Combinatorial Library Induces Virus-Neutralizing Antibodies and Reduces Viral Load In Vivo , 1998, Journal of Virology.
[28] D. Moss,et al. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. , 1998, Journal of immunology.
[29] D. Chargelegue,et al. Reduction of respiratory syncytial virus titer in the lungs of mice after intranasal immunization with a chimeric peptide consisting of a single CTL epitope linked to a fusion peptide. , 1998, Virology.
[30] C. Leclerc,et al. The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. , 1997, Cellular immunology.
[31] X. Mo,et al. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. , 1996, Journal of immunology.
[32] H. Davis,et al. DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost. , 1996, Vaccine.
[33] J. Berzofsky,et al. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Reimann,et al. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. , 1995, Human gene therapy.
[35] F. Chisari,et al. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice , 1995, Journal of virology.
[36] J. Bell,et al. Selection of T cell receptor variable gene‐encoded amino acids on the third binding site loop: a factor influencing variable chain selection in a T cell response , 1995, European journal of immunology.
[37] J. Reimann,et al. Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. , 1994, Journal of immunology.
[38] F. Chisari,et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis , 1993, The Journal of experimental medicine.
[39] M. Feltkamp,et al. Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.
[40] P. Cresswell,et al. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I- restricted cell-mediated lysis , 1991, The Journal of experimental medicine.
[41] D. Ganem,et al. Mutational analysis of hepatitis B surface antigen particle assembly and secretion , 1991, Journal of virology.
[42] A. Vitiello,et al. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex , 1991, The Journal of experimental medicine.
[43] D. Gray,et al. Novel pathways of antigen presentation for the maintenance of memory. , 1991, International immunology.
[44] M. Perkins,et al. Primary respiratory syncytial virus infection in mice , 1988, Journal of medical virology.
[45] B A Askonas,et al. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus , 1988, The Journal of experimental medicine.
[46] Howard M. Goodman,et al. Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen , 1979, Nature.
[47] F. Guarnieri,et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.
[48] R. Gupta,et al. Adjuvants for human vaccines--current status, problems and future prospects. , 1995, Vaccine.